Skip to content
Disclosery

Commodore Capital LP

Follow

13F filer, CIK 1831942, NEW YORK, NY

Commodore Capital LP reported $1,416,719,296 across 33 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-14. Its ten largest share positions make up 62.23% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001831942-25-000008

Period
2025-06-30
Reported value
$1.42B
Holdings
33
Top 10 weight
62.23%
New
7
Sold out
5

Part of the filer group Commodore Capital LP

  • Commodore Capital Master LP
  • Michael Kramarz
  • Robert Egen Atkinson
How groups are built

Stakes and trades reported after 2025-06-30

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • SGMT SAGIMET BIOSCIENCES INC: 13G 5,507,752 shares, 7.6% of the class, 13G filed 2026-10-07, 0001831942-26-000045Timeline
    Accepted , ingested
  • SRZN SURROZEN INC: 13G 885,000 shares, 7.5% of the class, 13G filed 2026-10-01, 0001831942-26-000044Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
PTGXnew+1,075,000$59.4M
CDTXnew+1,175,000$57.2M
RLAYnew+13,350,000$46.2M
KYMRnew+750,000$32.7M
XENEadded+700,000$21.9M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
PCVXexited-1,650,000-$62.3M
MERUS N Vreduced-947,840-$49.9M
COGTreduced-6,581,652-$47.3M
SLNOreduced-540,000-$45.2M
VERAreduced-1,761,782-$41.5M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0001831942-25-000008, largest first. % of portfolio is the value over $1,416,719,296, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
MERUS N VMERUS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,350,000 shares; 2024Q4: 3,874,182 shares; 2025Q1: 4,472,840 shares; 2025Q2: 3,525,000 shares 3,525,000$185M13.09%-947,840
NUVLNUVALENT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 940,000 shares; 2024Q4: 1,621,600 shares; 2025Q1: 1,855,000 shares; 2025Q2: 1,375,000 shares 1,375,000$105M7.41%-480,000Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,700,000 shares; 2024Q4: 2,740,000 shares; 2025Q1: 2,325,000 shares; 2025Q2: 3,025,000 shares 3,025,000$94.7M6.68%+700,000Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,100,000 shares; 2024Q4: 4,205,000 shares; 2025Q1: 4,675,000 shares; 2025Q2: 4,692,809 shares 4,692,809$94.1M6.64%+17,809Timeline
AGIOAGIOS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 2,185,000 shares; 2025Q2: 2,325,000 shares 2,325,000$77.3M5.46%+140,000Timeline
CLDXCELLDEX THERAPEUTICS INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,618,937 shares; 2024Q4: not reported; 2025Q1: 3,200,000 shares; 2025Q2: 3,450,000 shares 3,450,000$70.2M4.96%+250,000Timeline
ALKSALKERMES PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,900,000 shares; 2024Q4: 2,300,000 shares; 2025Q1: 1,950,000 shares; 2025Q2: 2,450,000 shares 2,450,000$70.1M4.95%+500,000Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,550,124 shares; 2024Q4: 2,400,000 shares; 2025Q1: 3,600,000 shares; 2025Q2: 4,875,000 shares 4,875,000$68.2M4.81%+1,275,000Timeline
PTGXPROTAGONIST THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,075,000 shares 1,075,000$59.4M4.19%newTimeline
CDTXCIDARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,175,000 shares 1,175,000$57.2M4.04%newTimeline
SRRKSCHOLAR ROCK HLDG CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 950,000 shares; 2025Q1: 1,745,000 shares; 2025Q2: 1,450,000 shares 1,450,000$51.4M3.63%-295,000Timeline
SLNOSOLENO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,260,000 shares; 2024Q4: 1,525,000 shares; 2025Q1: 1,150,000 shares; 2025Q2: 610,000 shares 610,000$51.1M3.61%-540,000Timeline
RLAYRELAY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 13,350,000 shares 13,350,000$46.2M3.26%newTimeline
NRIXNURIX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,650,000 shares; 2024Q4: 3,000,000 shares; 2025Q1: 3,978,907 shares; 2025Q2: 3,948,653 shares 3,948,653$45M3.17%-30,254Timeline
CNTACENTESSA PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,350,000 shares; 2024Q4: 2,218,425 shares; 2025Q1: 2,367,578 shares; 2025Q2: 3,298,289 shares 3,298,289$43.3M3.06%+930,711Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,911,433 shares; 2024Q4: 1,911,433 shares; 2025Q1: 1,911,433 shares; 2025Q2: 1,911,433 shares 1,911,433$33.6M2.37%0Timeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 750,000 shares 750,000$32.7M2.31%newTimeline
MIND MEDICINE MINDMED INCMIND MEDICINE MINDMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 8,000,000 shares; 2024Q4: 4,308,425 shares; 2025Q1: 4,525,000 shares; 2025Q2: 5,000,000 shares 5,000,000$32.5M2.29%+475,000
SYRESPYRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,988,084 shares; 2024Q4: 1,988,084 shares; 2025Q1: 1,988,084 shares; 2025Q2: 1,988,084 shares 1,988,084$29.8M2.1%0Timeline
TYRATYRA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 950,000 shares; 2025Q2: 3,100,000 shares 3,100,000$29.7M2.09%+2,150,000Timeline
VERAVERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,475,000 shares; 2024Q4: 1,958,600 shares; 2025Q1: 2,561,782 shares; 2025Q2: 800,000 shares 800,000$18.8M1.33%-1,761,782Timeline
CTMXCYTOMX THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 7,692,300 shares 7,692,300$17.5M1.23%newTimeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 7,539,930 shares; 2024Q4: 6,881,629 shares; 2025Q1: 8,892,816 shares; 2025Q2: 2,311,164 shares 2,311,164$16.6M1.17%-6,581,652Timeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,369,714 shares; 2024Q4: 1,419,714 shares; 2025Q1: 1,419,714 shares; 2025Q2: 1,419,714 shares 1,419,714$15.9M1.12%0Timeline
DRUGBRIGHT MINDS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 500,000 shares; 2025Q1: 500,000 shares; 2025Q2: 500,000 shares 500,000$13.1M0.92%0Timeline
APGEAPOGEE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 290,000 shares; 2024Q4: 290,000 shares; 2025Q1: 290,000 shares; 2025Q2: 290,000 shares 290,000$12.6M0.89%0Timeline
IKTINHIBIKASE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 5,925,000 shares; 2025Q1: 5,344,432 shares; 2025Q2: 5,397,488 shares 5,397,488$10.5M0.74%+53,056Timeline
FRNMPERCEPTIVE CAP SOLUTIONS CORQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 750,000 shares; 2024Q4: 750,000 shares; 2025Q1: 750,000 shares; 2025Q2: 750,000 shares 750,000$7.96M0.56%0Timeline
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,500,000 shares 1,500,000$7.68M0.54%newTimeline
CBIOCRESCENT BIOPHARMA INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 453,686 shares 453,686$7.32M0.52%newTimeline
NGNENEUROGENE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 200,000 shares; 2024Q4: 800,000 shares; 2025Q1: 925,000 shares; 2025Q2: 427,866 shares 427,866$6.4M0.45%-497,134Timeline
VTGNVISTAGEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,575,000 shares; 2024Q4: 1,575,000 shares; 2025Q1: 1,575,000 shares; 2025Q2: 1,575,000 shares 1,575,000$3.15M0.22%0Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 483,000 shares; 2024Q4: 483,000 shares; 2025Q1: 483,000 shares; 2025Q2: 483,000 shares 483,000$2.41M0.17%0Timeline

Sold out in Q2 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
PCVXVAXCYTE INC1,650,000$62.3Mshares
SLDBSOLID BIOSCIENCES INC5,825,000$21.6Mshares
CRDFCARDIFF ONCOLOGY INC5,384,616$16.9Mshares
ORICORIC PHARMACEUTICALS INC2,000,000$11.2Mshares
CELCCELCUITY INC695,650$7.03Mshares

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001831942-25-000008 base2025-08-14acceptance time not in the bulk data set